Bharat Parenterals Limited has announced a key senior management appointment, naming Mr. Keval Sanjaykumar Shah as Vice President - Operations effective January 01, 2026. The pharmaceutical company made this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The company has formally approved the appointment of Mr. Shah as a senior management personnel in the Vice President - Operations role. The appointment takes effect from January 01, 2026, with no specific term mentioned for the position.

Professional Background

Mr. Keval Shah brings substantial experience to his new role at Bharat Parenterals Limited. He holds an MBA degree from IMT Ghaziabad and has accumulated over 10 years of professional experience across multiple business functions.

His expertise spans several critical areas:

• Supply chain management
• Project management
• Team leadership
• Vendor management
• Business development

Leadership Profile

According to the company's disclosure, Mr. Shah is characterized as a young, dynamic, and results-driven business professional. His educational background and diverse experience have equipped him with a holistic and practical approach to both strategic decision-making and daily operations.

The company highlighted that his strong foundation in operations management and overall business administration, combined with his deep industry expertise and leadership capabilities, will be instrumental in advancing the organization's next phase of growth.

Regulatory Compliance

The appointment announcement was made in compliance with SEBI regulations, specifically under Regulation 30 read with Para A of Part A of Schedule III of the Listing Regulations. The disclosure also adheres to requirements outlined in SEBI Master Circular No SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Company Secretary and Compliance Officer Sharmin Soni signed the regulatory filing, ensuring proper documentation and compliance with all applicable disclosure requirements. The appointment represents a strategic addition to the company's senior management team as it continues to strengthen its operational capabilities.

Bharat Parenterals Limited, a key player in the pharmaceutical sector, has reported a significant decline in its standalone revenue for the second quarter of fiscal year 2026. Despite the revenue drop, the company remains optimistic about its future performance and has maintained its guidance for the full fiscal year.

Q2 FY26 Financial Highlights

The company's revenue saw a substantial decrease of 35.35% year-over-year, primarily attributed to planned production upgrades and deferred export dispatches. Despite this temporary setback, Bharat Parenterals has reaffirmed its commitment to growth and profitability for the full fiscal year.

FY26 Guidance Maintained

Bharat Parenterals has maintained its guidance for FY26, demonstrating confidence in its long-term strategy:

• Revenue Growth: 12-14%
• EBITDA Margins: 15-17%

This outlook suggests that the company expects to recover from the Q2 dip and achieve substantial growth over the course of the fiscal year.

Subsidiary Performance

Innoxel, a subsidiary of Bharat Parenterals, has reported significant developments:

• Achieved US FDA approval
• Signed 7 new partnerships
• Total value of new partnerships: $1.85 million

These achievements by Innoxel are expected to contribute positively to the parent company's performance in the coming quarters.

Looking Ahead

While the Q2 FY26 results show a temporary decline in revenue, Bharat Parenterals' maintained guidance and its subsidiary's achievements indicate a positive outlook for the company. The planned production upgrades, once completed, may potentially lead to improved efficiency and output in the future.

Investors and market watchers will likely keep a close eye on how the company navigates the challenges of deferred exports and capitalizes on the opportunities presented by its subsidiary's recent successes.